Escient Pharmaceuticals' Series A Round

Escient Pharmaceuticals raised a round of funding on April 09, 2018.

Escient Pharmaceuticals is working on G Protein-Coupled Receptor (GPCR)-targeted drugs to address serious, unserved medical needs across a broad range of therapeutic indications.…

Articles about Escient Pharmaceuticals' Series A Round: